Yep exactly. Definitely a very high risk/reward stock. Initial positive results though would be huge with all the other clinicals supposedly underway. I guess we'll find out sooner or later.
This is a device that will get orphan status and fast tracked meaning it will take a fraction of the time and money to get through FDA trials that's the TRUTH!
21st century cure acts is a big plus for ENDV!
These preclinical trials are a huge step for the biotech industry. ENDV is creating a whole new space of non invasive approach to treat vital organs this is Multi billion dollar company in the making.
News 
Market Data 
Discover 
